Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
WHO’s first ever global estimates of foodborne diseases: children under five account for almost one third of deaths Almost one third (30%) of all deaths from foodborne diseases are in children under the age of five years, despite the fact that they make up only 9% of the global population.
Newborn heel prick screening starts on St Eustatius and Saba On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.
Flu season in the winter of 2014 / 2015 more severe and longer than preceding years The flu epidemic in the winter of 2014 / 2015 lasted 21 weeks and as such was the longest epidemic ever recorded in the Netherlands. Nearly two million people suffered from flu-like symptoms.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.